NHS and NICE recommend sponge test for esophageal cancer screenings in draft guidelines

Source: Medtronic
The UK’s National Health Service has released draft guidelines for esophageal cancer screenings, recommending a new sponge test that is less invasive than an endoscopy. The screen would test for esophageal cancer, as well as Barrett’s oesophagus, a condition that increases the risk for esophageal cancer. Around 9,500 people in the UK develop esophageal cancer each year, and less than 30% of those diagnoses were early stage cancers.
What is Barrett’s oesophagus?
People with consistent acid reflux, heartburn, or persistent indigestion are likely to develop a condition called Barrett’s oesophagus. This condition develops when constant damage from stomach acid predisposes cells in the lining of the esophagus to becoming cancerous. Acid reflux can be caused by a weakened stomach sphincter, allowing acids to backflow upwards, and is more common in overweight individuals, smokers, and heavy drinkers.
While not everyone with Barrett’s develops cancer, 3 to 13% of them will develop cancer in their lifetime. Knowing that they are at risk allows them to proactively monitor their symptoms, and catch esophageal cancer at an earlier and more treatable stage if they do develop it.
What does the new sponge test do?
The sponge test involves patients swallowing a special capsule connected to a thread. After it enters the stomach, the capsule will dissolve and release a sponge, still connected to the thread. This sponge will be pulled back upwards through the esophagus after a few minutes. As it is being pulled out through the mouth, the sponge will collect cells that can be tested in the laboratory. The whole test only takes around seven minutes.
Research found that many people preferred the sponge test to the endoscopy, which is the more common procedure for esophageal cancer screenings. This more invasive procedure requires a tube with a camera to be inserted through the mouth as the patient is sedated. Compared to the sponge test, which is quick and non-invasive, the endoscopy also carries other disadvantages for large-scale screening, such as a longer duration, the need for more staff involvement, risks such as bleeding, and high demand, which leads to some concerned patients being overlooked for screening.
Recommendations from NHS and NICE
The National Institute for Health and Care Excellence (NICE), an advisory body for the NHS, recommends two sponge tests in particular, Cytosponge from Medtronic and EndoSign from Cyted Health, for NHS deployment in a draft guidance. These sponge tests are already being offered in places other than the UK, and are the first of NICE’s recommendations under the National HealthTech Access Programme, which searches for the latest health technologies and assesses their feasibility for NHS rollout.
Professor Jonathan Benger, chief executive of NICE, asserted the value of the test for esophageal screening. “Oesophageal cancer is very difficult to treat when it is diagnosed at a later stage, so identifying people sooner is really important… This new technology has the potential to make testing easier for patients, while helping the NHS focus valuable endoscopy capacity on those who need it most.”
As Professor Peter Johnson, the national clinical director from NHS England, reiterated, “The NHS is always looking for better ways to get to the bottom of people's symptoms, and thousands have already benefited from this incredibly efficient test through pilots we have been running, so it's fantastic it is now being considered for roll out across the country.”
Prof. Johnson also emphasized the need for less resource-intensive ways to screen the population for esophageal cancer risk. “Many people have acid reflux, and having an easier way to check for changes in the lining of the oesophagus can make a big difference for patients, reducing the need for more complicated endoscopy tests and helping the NHS free up resources to find cancers at an earlier stage."
While NICE will finalize their recommendation in early 2027, they still caution that the sponge test cannot identify all cases. People at risk of Barrett’s esophagus cleared by the sponge test should still undergo regular screening in case they develop the disease or cancer.
